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Repeat length of the CAG microsatellite polymorphism in exon 1 of the androgen receptor (AR) gene has been
associated with risk of prostate cancer in humans. This association has been the focus of 120 primary epidemiological
publications and multiple review articles, but a consistent and reproducible association has yet to be confirmed.
We systematically addressed possible causes of false-negative and false-positive association in 14,000 individuals
from a multiethnic, prospective cohort study of prostate cancer, comprehensively studying genetic variation by
microsatellite genotyping, direct resequencing of exons in advanced cancer cases, and haplotype analysis across the
180-kb AR genomic locus. These data failed to confirm that common genetic variation in the AR gene locus
influences risk of prostate cancer. A systematic approach that assesses both coding and noncoding genetic variation
in large and diverse patient samples can help clarify hypotheses about association between genetic variants and
disease.
Introduction
Irreproducibility is a major issue in association studies
(Lohmueller et al. 2003), and many factors can contrib-
ute to both false-negative and false-positive results. Pos-
sible explanations for irreproducibility include false-nega-
tive results due to inadequately powered studies, with
sample sizes that are small relative to the true effect size
(Cardon and Bell 2001) and inadequate characterization
of genetic variation at the locus of interest; false-positive
results due to inappropriately generous P value thresh-
olds (Wacholder et al. 2004); and the possibility of ethnic
heterogeneity in causal mutations (due to unmeasured
genetic or environmental confounders). It is vital to dis-
tinguish true associations from false-positive results: a
confirmed genetic association provides proof that a given
pathway plays an etiological role in disease and, as such,
lays the groundwork both for the development of drugs
for treatment and/or prevention of disease and for the
development of tests that could guide prediction, prog-
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nosis, and choice of therapy. Because downstream bio-
logical and clinical follow-up of positive findings demand
substantial investments of time and money, however, it
is essential to rigorously demonstrate the validity of pu-
tative associations, lest investment be wasted on the basis
of spurious claims of association.
One important example is that of an association be-
tween genetic variation in the androgen receptor (AR)
gene and risk of prostate cancer. Androgens play a criti-
cal role in development of the prostate gland, and block-
ade of androgen signaling is a mainstay of prostate can-
cer treatment. In the human population, the AR gene
sequence varies in a manner that influences protein func-
tion: rare and dramatic expansions (140 repeats) of a
CAG microsatellite polymorphism in the coding region
of AR cause spinal and bulbar muscular atrophy (MIM
313200), whereas common and more modest variation
in the length of this same CAG repeat (population mean
repeats  SD equals ) influences transactivation22  3
activity in vitro (Mhatre et al. 1993; Chamberlain et al.
1994; Beilin et al. 2000). For these reasons, the CAG
polymorphism has been extensively studied for associa-
tion with prostate cancer in cohorts of various sizes,
many of which claim positive results (Irvine et al. 1995;
Giovannucci et al. 1997; Ingles et al. 1997; Stanford et
al. 1997; Bratt et al. 1999; Correa-Cerro et al. 1999;
Edwards et al. 1999; Ekman et al. 1999; Hsing et al.
2000; Lange et al. 2000; Xue et al. 2000; Beilin et al.
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2001; Latil et al. 2001; Modugno et al. 2001; Panz
et al. 2001; Balic et al. 2002; Chen et al. 2002; Gsur
et al. 2002; Mononen et al. 2002; Huang et al. 2003;
Santos et al. 2003; Cicek et al. 2004)—albeit without
emergence of a single model of genotype-phenotype cor-
relation as consistently associated (for recent reviews,
see Nelson and Witte [2002] and Simard et al. [2003]).
Although not every study reported a positive associa-
tion, inability to replicate has been attributed to inade-
quate sample size and/or to poor study design in reports
of negative association (Kantoff et al. 1998; Buchanan
et al. 2001; Coetzee and Irvine 2002; Nelson and Witte
2002).
To help clarify the relationship between inherited
variation in the AR locus and prostate cancer, we sys-
tematically evaluated the common genetic variation at
the AR locus in a large, multiethnic cohort of patients
with sporadic prostate cancer.
Materials and Methods
The Multiethnic Cohort Study
Case and control subjects in the prostate cancer study
were the male participants, from Hawaii and Los An-
geles, in the Multiethnic Cohort Study (MEC). Details
of the study have been published elsewhere (Kolonel et
al. 2000). Briefly, 1200,000 men and women, aged 45–
75 years and residing in Hawaii and California, com-
pleted a questionnaire that included requests for data
on demographic characteristics (including self-reported
ancestry), lifestyle, health behaviors, and diagnoses, as
well as a comprehensive dietary survey. Response rates
were 72% for cases and 70% for controls.
Participants in the MEC are followed for incident can-
cers by computer linkage of the cohort with the Sur-
veillance, Epidemiology, and End Results (SEER) cancer
registries in Hawaii and Los Angeles, as well as with the
California Cancer Registry. A total of 2,036 subjects with
prostate cancer and 2,160 controls are included in the
present study. Only incident cases from the African Am-
erican, Japanese, Latino, and white sub-cohorts are in-
cluded this study. A random sample of MEC participants
was selected for blood collection, to serve as a cohort-
based control for genetic analyses.
SNP Genotyping
SNPs were identified in both the public (dbSNP) and
private (Celera) databases. The Sequenom MassArray sys-
tem at Broad Institute was used to genotype the SNPs,
as described elsewhere (Gabriel et al. 2002). In brief,
primers and probes were designed for each SNP by the
SpectroDesign software (FASTA sequences and primers
and probes are available on request). Multiplex PCR was
performed in 5-ml volumes that contain 0.1 U of Taq
polymerase (Amplitaq Gold, Applied Biosystems [ABI]),
5 ng genomic DNA, 2.5 pmol of each PCR primer, and
2.5 mmol of dNTP. Thermocycling was at 95C for 15
min, followed by 45 cycles of 95C for 20 s, 56C for
30 s, and 72C for 30 s. Unincorporated dNTPs were
deactivated using 0.3 U of shrimp alkaline phosphatase
(Roche), followed by primer extension by use of 5.4 pmol
of each primer extension probe, 50 mM of the appro-
priate dNTP/ddNTP combination, and 0.5 units of Ther-
mosequenase (Amersham Pharmacia). Reactions were
cycled at 94C for 2 min, followed by 40 cycles of 94C
for 5 s, 50C for 5 s, and 72C for 5 s. After addition
of a cation-exchange resin to remove residual salt from
the reactions, ∼7 nl of the purified primer-extension re-
action was loaded onto a matrix pad (3-hydroxypicol-
inic acid) of a SpectroCHIP (Sequenom). SpectroCHIPs
were analyzed using a Bruker Biflex III MALDI-TOF
mass spectrometer (SpectroREADER [Sequenom]) and
were spectra processed using SpectroTYPER (Sequenom).
Successful genotyping assays were defined as those in
which 75% of all possible genotyping calls were ob-
tained. Although we used 75% as a minimum threshold,
we obtained an average of 90.5% for all genotypes at-
tempted for each successful SNP.
Sequencing
The exons of the AR gene were sequenced in DNA
from 88 subjects with advanced prostate cancer, includ-
ing 22 individuals from each of the four self-described
ethnic groups—African American, white, Japanese, and
Latino. Primers were designed to capture the full exonic
sequence. First, amplification of the target site was per-
formed. We used 22.5 ng of genomic DNA as template
DNA. Each reaction consisted of a final volume of 30
ml; the final concentration for each reagent was 1.5 mM
of MgCl2, 10# PCR Buffer II, 0.3 ml of 10mM dNTPs,
5 U/ml of AmpliTaq Gold, 0.017 mM mixed forward and
reverse primers, and sterile water. This reaction was cy-
cled under the following conditions: 96C for 10 min,
35 cycles of 96C for 30 s, 50C for 2 min, and 72C
for 2 min, followed by 72C for 2 min. We amplified
sequences with PCR primers tailed with standard M13
sequencing sites (21 forward and 28 reverse) and
performed conventional dye-primer sequencing on ABI
377 sequencers. Sequences were base-called by the Phred
program and assembled by the Phrap program, and poly-
morphism candidates were identified by the PolyPhred
program. All results were visually inspected by at least
two observers to confirm or refute the automated geno-
typing call.
Microsatellite Genotyping
Primers (5′-TCCAGAATCTGTTCCAGAGCGTGC-3′
and 5′-GCTGTGAAGGTTGCTGTTCCTCAT-3′) were
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used to PCR amplify the region flanking the CAG mi-
crosatellite repeat in exon 1 of the AR. One of the prim-
ers was 5′-modified with the fluorescent dye FAM. Prod-
ucts were analyzed by fragment analysis on an ABI 3730.
The final reaction volume per reaction was 6 ml and com-
prised 5 ng of template DNA combined with 10# PCR
buffer, 0.8 mM MgCl2, 0.2 mM dNTPs, 0.8 mM each
of forward and reverse primers, 0.04 ml of HotStarTaq
(Qiagen), and water (units given are for the final con-
centration). This mixture was placed in a thermal cycler
(MJ Research) with the following settings: 92C for 15
min; 94C for 20 s, 56C for 30 s, 72C for 1 min, and
45 cycles at 72C for 3 min. After cycling, each product
was diluted 15-fold, and 2 ml of this dilution was added
to each well. Then, 8 ml of Genescan 500-LIZ size
standard:formamide mix (1:33) was added to each well.
Products were electrophoresed on an ABI 3730 capillary
sequencer. The data were analyzed by Genemapper soft-
ware that automatically called fragment sizes relative to
the ladder, to account for any migration artifact.
Known CAG lengths were sequenced for 60 individ-
uals. The 60 individuals were split into two groups of
30—one group was used as a training set to derive the
best fit for calculating the number of CAG repeats from
the fragment length. The second group of 30 individuals
was used as a test set to test the equation derived from
the training set. We found that the equation y(number of
CAG # (fragment length)80.577repeats) p 0.3682
gave 100% accuracy.
Haplotype-Block Definition and Haplotype-Phase
Determination
Haplotype blocks were determined using criteria de-
scribed by Gabriel et al. (2002), on the basis of a com-
posite of pairwise D′ values (Lewontin 1964). Empirical
evidence shows that regions that meet the block defi-
nition of Gabriel et al. (2002) and that contain at least
six SNPs have two properties: !5% of SNP pairs within
such regions show strong evidence for recombination,
and, within such regions, haplotype diversity is typically
low.
Because the AR resides on the X chromosome and we
studied men, haplotypes could be directly observed from
genotype data without the need for statistical phasing.
Missing data were resolved by use of the EM algorithm
(Excoffier and Slatkin 1995).
Statistical Analysis
Unconditional logistic regression was used to analyze
the resultant case and control data (SAS statistical soft-
ware, version 8.0 [SAS Institute]). Analyses were con-
ducted using the genetic data alone, adjusted for race/
ethnicity as well as for stratification on race/ethnicity and
disease severity. The haplotype analyses were performed
by comparison of one haplotype with all others (reported
in the “Results” section) as well as by use of the most
common haplotype as a reference haplotype (data not
shown). Both methods yielded similar nonsignificant re-
sults. Disease severity for cases was categorized into ei-
ther “local” or “advanced” disease. “Local” was defined
as “local disease with a well- or moderately differenti-
ated grade”; “advanced” was used to mean “either local
disease with a poorly differentiated grade” or “regional
or distant disease.” Significance levels are reported two-
sided and have not been corrected for multiple-hypothe-
sis testing. The odds ratio (OR) is the ratio of the odds
in favor of exposure among the cases to the odds in
favor of exposure among the controls.
Among controls, analysis of variance was used to evalu-
ate differences in CAG microsatellite repeat length across
self-described ethnic groups. Unconditional logistic re-
gression was used to model the association between re-
peat length and risk of prostate cancer. Repeat length was
modeled using several approaches (continuous variable
and cut point at !22 and !23 repeats) on the basis of
previous literature. Analyses were adjusted for race/eth-
nicity, when combined. Analysis was also conducted to
explore the role of disease severity and age with the
association between repeat length and risk of prostate
cancer. Both categorical and linear models were fit for
the CAG repeat analysis; a categorical model did not
provide a better fit to the data ( ).P p .98
For sequencing, the formula used for the power to de-
tect a variant was: Power , where p is thenp 1  (1  p)
allele frequency and n is the number of chromosomes.
Results
We first studied the CAG-repeat polymorphism in exon
1 of the AR gene in 4,196 individuals from the prospec-
tively collected MEC: 2,036 subjects with incident pros-
tate cancer and 2,160 ethnically matched cohort controls
(see tables A1 and A2 [online only] for descriptive char-
acteristics). To our knowledge, this is the largest study
of this variant in sporadic prostate cancer (nearly four
times the size of the previous largest study) as well as
the first to examine a large African American population,
who suffer from particularly high rates of prostate can-
cer (Kolonel et al. 2000; Quinn and Babb 2002; SEER).
As a primary analysis, we used unconditional logistic
regression to examine the relationship between CAG-
repeat length (as a continuous variable) and risk of pros-
tate cancer. We found no evidence of heterogeneity
among the ethnic groups, with regard to measures of
association ( ) (table 1), and thus present dataP 1 .05
pooled across ethnic groups with adjustment for age and
ethnicity as covariate.
We failed to detect a nominally significant association
between CAG length and prostate cancer risk (OR 1.016
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Table 1
Association Analysis of CAG Repeat Polymorphism (Continuous Variable), Stratified by Self-Reported Ethnicity
SUBJECTS
FINDINGS BY ETHNIC GROUP
African American Japanese Latino White
ORa 95% CI P ORa 95% CI P ORa 95% CI P ORa 95% CI P
All cases 1.014 .982–1.047 .40 1.006 .962–1.052 .79 1.015 .978–1.055 .43 1.032 .986–1.080 .17
Advanced cases .983 .937–1.032 .50 1.064 1.001–1.130 .05 .993 .943–1.047 .8 1.055 .987–1.126 .11
Local cases 1.022 .985–1.060 .24 .972 .923–1.024 .28 1.028 .984–1.073 .22 1.017 .964–1.073 .87
a Adjusted for age.
Table 2
Continuous and Cut Point Analyses of Prostate Cancer Risk with Decreased CAG-Repeat Length
SUBJECTS
NO. OF
CONTROLS/CASES
FINDINGS FOR CAG-REPEAT LENGTH
Continuous !22 versus 22 !23 versus 23
ORa 95% CI Pb ORa 95% CI Pb ORa 95% CI Pb
All cases 2,160/2,036 1.016 .997–1.036 .11 1.084 .954–1.231 .22 1.115 .981–1.267 .09
Advanced cases 2,160/686 1.015 .988–1.044 .28 1.094 .913–1.310 .33 1.122 .936–1.345 .21
Local cases 2,160/1,239 1.013 .991–1.036 .25 1.068 .922–1.238 .38 1.087 .937–1.261 .27
NOTE.—There is no statistically significant association between the CAG-microsatellite polymorphism and prostate cancer risk
for the entire population or when stratified by stage. Multiple analyses were performed, by using two cut points (22 and 23) as
well as by modeling the CAG-repeat length as a continuous variable. These analyses demonstrate no significant association between
prostate cancer risk and CAG-repeat length.
a Adjusted for race/ethnicity and age.
b Two-sided P value.
per CAG decrement; 95% CI 0.997–1.036; ) (ta-P p .11
ble 2). Because the previous literature on AR and prostate
cancer provided a prior hypothesis as to the direction of
the effect (that shorter repeat lengths are associated with
increased risk), our result could be considered a one-sided
test with a P value of .055 and thus borderline significant
for replication. Because the study sample is large, how-
ever, our results provide very tight CIs on the estimate
of risk: on the basis of our result, for example, we expect
that, on repeated sampling, an OR between 0.99 and
1.036 would be observed 95% of the time.
The literature that examines association of the AR and
prostate cancer includes many different models for analy-
sis of genotype (with consideration of repeat length as a
threshold variable, for example, rather than as a con-
tinuous variable) and phenotype (with consideration of
association analysis on a particular age at onset or status,
such as advanced disease) (Giovannucci et al. 1997; Bratt
et al. 1999). On the hypothesis that one of these models
might provide a more reproducible and substantial as-
sociation, we examined, as a secondary analysis, a va-
riety of these models, including different cut points for
repeat length (!22/22 and !23/23) and age at di-
agnosis. We found no significant evidence for associa-
tion between the CAG polymorphism and cancer risk
in any previously described model of genotype-pheno-
type correlation (tables 2 and A3 [online only]). The
results in each ethnic subgroup (table 1) are neither nomi-
nally significant nor statistically distinguishable from the
null result of the pooled sample. (On the causal hy-
pothesis that the CAG repeat influences—either directly
or by modification—the risk of prostate cancer, and
absent any as-yet-uncharacterized gene-by-environment
or gene-by-gene interaction, we would expect an effect
of CAG length in all ethnic groups examined—and thus
the best powered and most accurate estimate—to be
that provided by all participants in the study adjusted
for ethnicity.)
Given this very limited evidence for association be-
tween the CAG repeat and prostate cancer risk, we next
considered the possibility that previous positive results
had been due to linkage disequilibrium (LD) between the
CAG repeat and some other (as-yet-undetected) causal
variation in the AR gene region. To evaluate this pos-
sibility, we directly examined the coding region of the
AR gene to search for protein-altering mutations, and
we performed a detailed haplotype analysis spanning
the AR gene region, on the hypothesis that noncoding
(presumed regulatory) variants might play a role.
We resequenced each of the eight exons of the AR gene
in 88 men with advanced prostate cancer: 22 each from
the self-reported white, African American, Japanese, and
Latino ethnic groups. Two synonymous changes (G213G
in exon 1 and K581K in exon 2) were identified, but
no novel amino acid–altering variants were found. This
sample size provides 90% power to detect coding changes
86 Am. J. Hum. Genet. 76:82–90, 2005
Figure 1 SNPs and LD across the AR locus. A, Physical relationship of SNPs to the AR locus (from University of California–Santa Cruz
Genome Bioinformatics build hg16); 32 working polymorphic SNPs were genotyped across the AR locus, which spanned a total of 275 kb—the
SNPs covered from 56 kb upstream to 37 kb downstream of the AR gene. Using previously defined criteria (see the “Materials and Methods”
section), these 32 markers describe two strong blocks of LD (188 kb and 66 kb) with gaps between adjacent blocks (bounded by the markers
selected) of 11.9 kb. B, LD plot for entire population across the AR locus. Each square in the plot represents the pairwise LD relationships
among all 32 markers. The two blocks (see the “Materials and Methods” section) are highlighted and are bounded by markers 1–25 and 26–
32. Red denotes strong LD (as measured by D′) with a high degree of statistical confidence, pale blue denotes a high D′ with relatively low
statistical confidence, and white denotes low D′.
present in cases at a frequency of 3% or higher (in this
pooled sample), which suggests that germline protein-
altering mutations in the AR are rarely encountered,
even in patients with advanced prostate cancer.
We next examined the hypothesis that there might be
common noncoding variants that influence risk of pros-
tate cancer (e.g., by alteration of gene expression). Be-
cause it is not yet possible to recognize regulatory vari-
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Table 3
OR, 95% CI, and P Value for the Minor Allele of Each AR SNP
and Risk of Prostate Cancer (All Racial/Ethnic Groups Combined)
SNP
FINDINGS FOR THE MINOR ALLELE OF EACH AR
SNP AND RISK OF PROSTATE CANCER
All Cases Advanced-Stage Cases
ORa 95% CI Pb ORa 95% CI Pb
rs6525177 .93 .61–1.42 .75 .89 .50–1.57 .69
rs12557549 2.32 .44–12.31 .32 2.49 .33–19.03 .38
rs5964602 .90 .60–1.36 .61 .85 .49–1.48 .56
rs962458 1.22 .79–1.89 .36 1.40 .80–2.46 .24
rs12007229 .75 .48–1.18 .21 .51 .26–1.01 .05
rs6152 1.15 .79–1.66 .47 1.24 .77–2.0 .37
rs1204041 .61 .36–1.03 .07 .42 .20–.90 .02
rs1204040 1.20 .80–1.79 .37 1.09 .64–1.86 .76
rs1204038 .88 .59–1.33 .55 .85 .49–1.46 .56
rs2361630 1.17 .81–1.71 .41 1.29 .79–2.12 .31
rs1926925 .58 .33–1.02 .06 .35 .15–.86 .02
rs1926926 .55 .32–.96 .04 .29 .11–.72 .01
rs1926927 .54 .31–.95 .03 .33 .14–.81 .01
rs2361634 .62 .26–1.48 .28 1.09 .39–3.0 .88
rs2361636 .46 .25–.86 .01 .28 .10–.75 .01
rs1361039 1.35 .29–6.39 .70 2.26 .35–14.48 .39
rs1337077 .63 .36–1.10 .11 .41 .18–.96 .04
rs1337078 .58 .33–1.02 .06 .40 .17–.92 .03
rs1337079 .57 .32–.99 .05 .34 .14–.81 .02
rs1337080 .99 .62–1.57 .96 .83 .45–1.55 .56
rs1572500 .54 .30–.97 .04 .39 .16–.96 .04
ARa15 4.63 .47–45.9 .19 6.18 .52–74.03 .15
rs1337075 .56 .31–1.02 .06 .34 .13–.86 .02
rs1572501 3.19 .66–15.42 .15 .87 .08–10.13 .91
rs1361038 1.12 .57–2.19 .75 .85 .34–2.11 .73
rs1337076 1.07 .63–1.82 .81 .88 .44–1.78 .73
rs10060 1.01 .63–1.63 .97 .96 .52–1.78 .89
rs1337082 .96 .65–1.41 .84 .90 .54–1.49 .68
rs945052 .98 .59–1.61 .93 .85 .44–1.64 .62
rs945048 .94 .57–1.54 .80 .77 .39–1.50 .43
rs945050 .87 .61–1.25 .45 .81 .51–1.31 .40
rs1361037 1.10 .67–1.83 .71 .89 .45–1.76 .74
NOTE.—All 32 SNPs across the AR are individually tested for as-
sociation with prostate cancer in the entire MEC population.
a Adjusted for age and race/ethnicity.
b P values are two-sided, with no correction for multiple testing.
ants from primary sequence data, and, given the large
size of the AR gene region, complete resequencing in each
case and control subject was impractical. For this rea-
son, we used a haplotype-based approach to survey the
274 kb surrounding the AR gene locus. In total, 32 poly-
morphic SNPs (from the dbSNP and Celera databases)
were genotyped in each of 1,756 people (882 cases; 874
controls) (fig. 1A). (Since the AR is on the X chromo-
some, and since our analysis considered males only, hap-
lotype phase was directly observable from the genotype
data.) The genotype data show two regions character-
ized by strong LD, which meets criteria for haplotype
“blocks” as calibrated elsewhere (Gabriel et al. 2002)
(fig. 1B). More than 93% of haplotypes matched one
of the 4–8 haplotypes in each block, with a frequency
of 11% in the multiethnic sample (data not shown).
Given the number of markers typed, the strong LD ob-
served, and the fact that we had directly resequenced
the coding regions, we believe that the marker density
achieved thoroughly captures the common genetic varia-
tion across these 274 kb around the AR gene locus.
We examined association between prostate cancer risk
and each SNP and common haplotype in this subset of
men. No convincing association was observed (tables 3
and 4). The best results were two SNPs with a nominal
P value of .01, a value not unexpected by chance, given
32 SNPs tested for association with two phenotypes
(table 3). A combination of these results with the exon-
resequencing data suggests that if common genetic varia-
tion at the AR influences risk, it would be found outside
the coding region and demonstrate no LD with the well-
defined haplotype structure examined.
Discussion
One of the most vexing aspects of genetic-association
studies is the interpretation of results that prove incon-
sistent on subsequent data collection and analysis. Be-
cause confirmed associations are of great value in under-
standing pathways of disease, initial claims often attract
substantial attention. When subsequent studies fail to
reproduce results, it is difficult for investigators in both
the human genetic and biomedical communities to agree
on an interpretation of the data.
The growing literature relating genetic variation in
the AR gene to epidemiological risk of prostate cancer
is one such example. The AR is a compelling biological
candidate gene, and initial studies that reported asso-
ciation were well designed and highly suggestive of an
effect of the CAG-repeat variation on prostate cancer
risk. Since later reports collectively examined a variety
of methods of analysis and failed to reach a single uni-
fied model of genotype-phenotype correlation, there has
not been a clear and consistent picture of the impact of
this gene on prostate cancer risk. We hypothesized that,
by using a large sample and systematically examining
genetic variation across the region, we might help clarify
this association. The results were only marginally sugges-
tive for association of the CAG repeat (treated as a
continuous variable) and prostate cancer risk, with a
maximal effect size smaller than previously suggested.
What might explain the differences between our re-
sults and those published elsewhere? Because our study
is substantially larger than the studies that claimed more
strongly positive effects (Giovannucci et al. 1997; Stan-
ford et al. 1997; Mononen et al. 2002), it is unlikely that
our study represents a false-negative result for a true as-
sociation. Because we thoroughly searched coding re-
gions (by direct resequencing) and noncoding regions (by
haplotype analysis), it appears unlikely that we missed
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Table 4
Association of AR Haplotypes with Risk of Prostate Cancer
LD BLOCK (NO. OF CASES/CONTROLS)
AND HAPLOTYPE
FREQUENCY (%) AMONG
OR 95% CI PCases Controls
1 (843/805):
GCCGCAGAATACAAGGGAAAGCCTA 12.3 12.1 1.05 .77–1.44 .76
GCCGCAGAATACAAGGGAAGGCCTA 9.6 10.1 .96 .68–1.34 .79
GCCGCAAAATACAAGGGAAGGCCTG 5.7 6.3 .89 .59–1.36 .59
GCCGCAAAATACAAGGGAAGGCCCG 4.0 2.5 1.73 .98–3.06 .06
GCCAAAGAATACAAGGGAAAGCCTA 3.0 2.5 1.25 .65–2.40 .51
GCCAAGACACTTGAAGAGGATCTTA 9.4 12.2 .75 .54–1.04 .09
ACAACGGCGCACAAGGGAAAGCCTA 49.4 47.1 1.12 .85–1.48 .43
ACAACGGCGCACAGGGGAAAGCCTA 1.2 1.5 .73 .29–1.81 .49
2 (876/863):
GAGCACA 21.7 24.3 .88 .70–1.12 .30
GAACATA 49.6 46.7 1.09 .83–1.42 .53
GGGTTTG 10.2 9.7 1.15 .80–1.65 .46
TGGTTTG 16.7 16.4 1.09 .81–1.46 .56
NOTE.—Haplotypes are compared against all other haplotypes (see the “Materials and Methods”
section). No associations between common haplotype and prostate cancer are observed.
a true result because of an as-yet-undiscovered common
variant in the AR gene. Thus, our data suggest either
that the AR gene locus has (1) no effect on prostate
cancer risk, (2) an effect that is extremely small (!4%
per CAG repeat), or (3) an effect that is evident only
in certain (and as yet unidentified) subgroups of patients
that are based on an unmeasured genotypic, environ-
mental, or behavioral modifier. If the effect is small but
truly present, then even-larger samples (such as those
of the National Cancer Institute Cohort Consortium for
Breast and Prostate Cancer) will be needed to fully ad-
dress the contribution of such variants to prostate can-
cer risk. If the effect is seen only in a subgroup of pa-
tients, it will be difficult to demonstrate unless and until
the unmeasured confounding factors are identified.
Another class of a hypothesis for which the previous
effect was true—and which can explain nonreplication—
is that the definition and clinical characteristics of pros-
tate cancer may have changed over time. This hypothe-
sis is supported by the dramatic change in population
screening brought on by widespread testing of serum
levels of prostate-specific antigen (PSA). Since some of
the positive studies were reported prior to widespread
PSA testing, it is possible that failure of replication could
be secondary to a shift in the spectrum and characteris-
tics of prostate cancer cases detected by PSA, as com-
pared with prostate cancer cases ascertained prior to
PSA testing.
Obviously, we must consider the possibility that pre-
vious positive studies represent false-positive results due
to statistical fluctuation or to unrecognized population
stratification. Many of the previous studies showed only
modest statistical significance, and no single model of
genotype-phenotype correlation has consistently been ob-
served across many studies. Given the low Bayesian
prior probability that any one of the ∼30,000 genes in
the human genome plays a role in disease (even a strong
biological candidate like AR in prostate cancer) and the
modest P values obtained elsewhere, false-positive re-
sults are not unexpected (Hirschhorn and Altshuler
2002; Lohmueller et al. 2003; Wacholder et al. 2004).
False-positive association due to population stratifica-
tion is another possibility, and it is particularly relevant
in studies of prostate cancer (Kittles et al. 2002; Freed-
man et al. 2004). Prostate cancer is more common in
African Americans than in Americans of self-described
European ancestry, and African Americans have a lower
average repeat length at the exon 1 CAG than do whites
(Edwards et al. 1992; Sartor et al. 1999; the present
study). Thus, unrecognized population substructure
could lead to spurious association between CAG-repeat
length and prostate cancer risk (Pritchard and Rosen-
berg 1999; Kittles et al. 2002; Freedman et al. 2004).
Whether the samples studied in the past contained cryp-
tic substructure—and whether any such effect would
have been large enough to have influenced the prior
literature—has yet to be determined.
The causes of irreproducibility in any particular asso-
ciation of genotype and phenotype are difficult to iden-
tify and can be attributed to biological, statistical, or
technical reasons. From a practical point of view, how-
ever, those associations that are robust and reproducible
are the most certain to be biologically valid and of rele-
vance to patients in the average clinical setting. The
combination of a large, diverse patient sample and sys-
tematic evaluation of genetic variation in exons (by re-
sequencing) and surrounding genomic regions (by hap-
lotype analysis) provides a route for clarification of cor-
relations between genotype and phenotype and ad-
dresses each possible cause of false-positive and false-
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negative association. Development of a set of standards
for performing such validation studies will be increas-
ingly crucial as reports of genetic association proliferate
in the years to come.
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